Omnicell (NASDAQ:OMCL) Downgraded by StockNews.com to “Hold”

Omnicell (NASDAQ:OMCL) was downgraded by stock analysts at StockNews.com from a “buy” rating to a “hold” rating in a report issued on Friday.

A number of other brokerages also recently weighed in on OMCL. Bank of America reissued a “neutral” rating and set a $57.00 target price (up previously from $44.00) on shares of Omnicell in a research note on Thursday, October 31st. JPMorgan Chase & Co. lifted their price objective on Omnicell from $26.00 to $37.00 and gave the stock a “neutral” rating in a research report on Friday, August 23rd. Benchmark restated a “buy” rating and set a $48.00 target price on shares of Omnicell in a research report on Wednesday, October 9th. Wells Fargo & Company raised their target price on Omnicell from $30.00 to $41.00 and gave the stock an “equal weight” rating in a research note on Monday, October 14th. Finally, Craig Hallum boosted their price target on Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Five analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $50.83.

Omnicell Stock Performance

Omnicell stock opened at $45.67 on Friday. The firm has a market cap of $2.12 billion, a price-to-earnings ratio of -117.10, a PEG ratio of 46.03 and a beta of 0.81. Omnicell has a 52-week low of $25.12 and a 52-week high of $55.74. The firm has a 50 day moving average price of $44.20 and a two-hundred day moving average price of $36.82.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Texas Permanent School Fund Corp increased its holdings in shares of Omnicell by 1.2% during the first quarter. Texas Permanent School Fund Corp now owns 39,630 shares of the company’s stock valued at $1,158,000 after acquiring an additional 479 shares in the last quarter. SG Americas Securities LLC acquired a new position in Omnicell during the first quarter worth $684,000. Inspire Investing LLC raised its holdings in Omnicell by 19.2% during the first quarter. Inspire Investing LLC now owns 12,111 shares of the company’s stock worth $354,000 after buying an additional 1,952 shares during the last quarter. ProShare Advisors LLC lifted its stake in shares of Omnicell by 7.4% in the first quarter. ProShare Advisors LLC now owns 9,076 shares of the company’s stock valued at $265,000 after buying an additional 626 shares in the last quarter. Finally, Entropy Technologies LP acquired a new position in shares of Omnicell during the first quarter valued at about $227,000. 97.70% of the stock is owned by institutional investors and hedge funds.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.